Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Sulforaphane, a compound found in cruciferous vegetables like broccoli, has been investigated for its potential role in supporting or treating Chronic Obstructive Pulmonary Disease (COPD). The scientific rationale centers on sulforaphane’s ability to activate the Nrf2 pathway, which regulates the expression of antioxidant enzymes and helps counteract oxidative stress—a key factor in COPD pathogenesis. Several preclinical studies have shown that sulforaphane can attenuate oxidative stress and inflammation in animal models and cell cultures relevant to COPD. However, clinical evidence in humans is limited and somewhat inconclusive.

A notable randomized, double-blind, placebo-controlled trial (Wise et al., 2016, JAMA) investigated the effects of oral sulforaphane in COPD patients. The study found no significant improvement in markers of Nrf2 target gene expression or in clinical outcomes. While some smaller studies and mechanistic research suggest possible benefits, these have not translated convincingly into clinical efficacy.

In summary, while sulforaphane has a plausible scientific mechanism and preclinical support, current human clinical evidence does not robustly support its use for COPD. Therefore, sulforaphane’s use for COPD is justified by a scientific rationale, but the strength of clinical evidence remains low.

More about Sulforaphane
More about Chronic Obstructive Pulmonary Disorder

Other ingredients used for Chronic Obstructive Pulmonary Disorder

Other health conditions supported by Sulforaphane

Products containing Sulforaphane